News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Biocryst Pharmaceuticals (BCRX) Announces Nature Publication Demonstrating Efficacy Of BCX4430 In A Non-Human Primate Model Of Filovirus Infection



3/3/2014 8:58:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

RESEARCH TRIANGLE PARK, N.C., March 3, 2014 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced the online publication in the journal Nature of extensive laboratory and nonclinical characterizations of BCX4430, including efficacy results in animal models of infection with Marburg virus and Ebola virus, two highly virulent pathogens responsible for viral hemorrhagic fever diseases. The Nature online publication, "Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430," represents the first report of protection of non-human primates from filovirus disease by a small molecule drug, and describes efficacy results generated from an ongoing collaboration between scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and BioCryst.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES